HealthMyne delivers a QIDS platform that brings multiple enhanced clinical decision support (CDS) workflow modules to radiology and the oncology care continuum in a single platform. Its FDA-cleared Rapid Precise Metrics (RPM) algorithms automate extraction of quantitative imaging metrics at the Point-of-Read, reducing inter- and intra-reader variability and producing metrics such as volume, density, mass, doubling-times and heterogeneity. The platform combines volumetric measurements with clinical data from EMR, PACS, Radiation Therapy and other systems to power CDS modules (Cancer Screening, Tumor Board Management, Clinical Trials/Therapy Response Assessment, Incidental Findings, Thoracic Specialty) and generate actionable quantitative reports. HealthMyne also provides an integrated imaging and clinical patient-centric dashboard and a discoverable database that supports data mining and AI-based application development for precision medicine and research by medical centers and pharmaceutical/biotech companies. The company is focused on selling to U.S.-based multi-hospital systems with planned expansion to non-U.S. markets and other clinical specialties over time. HealthMyne recently raised $15 million in a Series B to expand global commercialization efforts. HealthMyne develops SAI (search, analytics, and imaging) technology that provides enhanced tumor image manipulation and EHR/image-repository search capabilities to support diagnosis and treatment decisions. The company’s first product, due to launch later this year, targets improved detection and diagnosis of lung nodules within a low dose CT lung screening program. HealthMyne positions its platform to deliver evidence-based imaging analysis and actionable insights at the point of care for radiologists and oncologists. The founding team, formed in 2013, includes entrepreneurs with prior start-up experience at TomoTherapy, Geometrics, and UltraVisual. The company recently completed a Series A financing to support its near-term product, regulatory, and commercialization efforts.

Total raised

$20M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2018